Evidence map›Paper›PMID 36325348›Full record

ArticleFrontiers in immunology2022

Glial receptor PLXNB2 regulates schizophrenia-related stress perception

Fang-Ling Xuan, Ling Yan, Yanli Li, Fengmei Fan, Hu Deng, Mengzhuang Gou, Keerthana Chithanathan, Indrek Heinla, Liang Yuan, Kadri Seppa and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Fang-Ling XuanInstitute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Ling YanInstitute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Yanli LiPsychiatry Research Centre, Beijing Huilongguan Hospital, Peking University Health Science Center, Beijing, China.
Fengmei FanPsychiatry Research Centre, Beijing Huilongguan Hospital, Peking University Health Science Center, Beijing, China.
Hu DengPsychiatry Research Centre, Beijing Huilongguan Hospital, Peking University Health Science Center, Beijing, China.
Mengzhuang GouPsychiatry Research Centre, Beijing Huilongguan Hospital, Peking University Health Science Center, Beijing, China.
Keerthana ChithanathanInstitute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Indrek HeinlaInstitute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Liang YuanDepartment of Medicine, Tufts Medical Center, Boston, MA, United States.
Kadri SeppaInstitute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Alexander ZharkovskyInstitute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Anti KaldaInstitute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
L Elliot HongMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, School of Medicine, Baltimore, MD, United States.
Guo-Fu HuDepartment of Medicine, Tufts Medical Center, Boston, MA, United States.
Yunlong TanPsychiatry Research Centre, Beijing Huilongguan Hospital, Peking University Health Science Center, Beijing, China.
Li TianInstitute of Biomedicine and Translational Medicine, Faculty of Medicine, University of Tartu, Tartu, Estonia.
University of Tartu · EEPeking University · CNTufts Medical Center · USBeijing HuiLongGuan Hospital · CNUniversity of Maryland, Baltimore · US

Funding

Protection and mitigation of bone marrow failure by angiogeninR01HL135160 · NHLBI · TUFTS MEDICAL CENTER · PI HU, GUO-FU · 2017 to 2020
$1.8M
The Role of Stress-Immune-Connectome Disruption in Mechanisms of Chinese Early Schizophrenia SpectrumR01MH112180 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI HONG, L ELLIOT ELLIOT · 2017 to 2021
$1.0M
NHLBI NIH HHS R01 HL135160NIMH NIH HHS R01 MH112180
6 · The paper itself

Abstract

Stress is a trigger for the development of psychiatric disorders. However, how stress trait differs in schizophrenia patients is still unclear. Stress also induces and exacerbates immune activation in psychiatric disorders. Plexins (Plxn) and its ligands semaphorins (Sema) are important cellular receptors with plural functions in both the brain and the immune system. Recently, the role of Plxn/Sema in regulation of neuroinflammation was also noticed. Here, when investigating immune mechanisms underlying stress susceptibility in schizophrenia, we discovered the role of Plxnb2 in stress response. Patients of first-episode schizophrenia (FES) with high stress (FES-hs,

Indexed as

SchizophreniaSemaphorinsAmygdalaAnimalsCopperLigandsMiceNerve Tissue ProteinsPerceptionCoppercupric sulfideLigandsNerve Tissue ProteinsPlxnb2 protein, mouseSemaphorinsamygdalaanxietyastrocytesfirst episode schizophreniamicrogliaPLXNB2stress

Identifiers

PMID36325348
PMCPMC9619215
OpenAlexW4306399553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.